Holen Sie sich die Stockscreener-App
109.86
2.73%
2.92
Handel nachbörslich:
109.86
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Argus raises target for Halozyme Therapeutics stock to USD 127 - AD HOC NEWS
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Halozyme appoints Jim Daly to board of directors - Investing.com
Halozyme adds James Daly to its Board of Directors - TradingView
Halozyme Therapeutics, Inc. Appoints James "Jim" Daly to Its Board of Directors - marketscreener.com
Price to cash flow ratio of Halozyme Therapeutics, Inc. – HAN:RV7 - TradingView
Halozyme Therapeutics, Inc. (HALO) Stock forecasts - Yahoo Finance Australia
Halozyme Therapeutics, Inc. Revenue Breakdown – HAN:RV7 - TradingView
Halozyme Therapeutics, Inc. Actuals & Estimates (HAN:RV7) - TradingView
ETFs Investing in Halozyme Therapeutics, Inc. Stocks - TradingView
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now - Eastern Progress
Halozyme stock falls 2.34% after strong quarterly growth - AD HOC NEWS
$1000 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth This Much Today - Benzinga
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength? - Yahoo Finance
Form 8K Halozyme Therapeutics Inc For: 22 September By Investing.com - Investing.com Canada
Halozyme Therapeutics completes $1.5 billion convertible notes offering By Investing.com - Investing.com Canada
Halozyme Therapeutics completes $1.5 billion convertible notes offering - Investing.com
Halozyme Therapeutics Raises $1.5 Billion in 1.50% Convertible Notes, Adds Capped Calls - TradingView
Halozyme Therapeutics, Inc. (HALO) stock price, news, quote and history - sg.finance.yahoo.com
Halozyme Therapeutics stock rises as $1.3 billion convertible notes fuel growth guidance - AD HOC NEWS
Halozyme (HALO) Just Made A $1.3B Bet On Itself - Yahoo Finance
Latham & Watkins Advises on Halozyme Therapeutics, Inc.’s Upsized US$1.3 Billion Convertible Senior Notes Offering - Latham & Watkins LLP
(HALO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate - Zacks Investment Research
Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost? - Yahoo Finance
Halozyme Therapeutics stock edges higher as investors weigh Q2 growth and pipeline risk - AD HOC NEWS
Halozyme Therapeutics (HALO) Rises 2.53% to $112.45, Testing Upper Half of Recent RangeBear Pennant - careplusvn.com
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) - easternprogress.com
Is Halozyme Therapeutics (HALO) Fully Valued As Growth Calls And Partnerships Draw Fresh Attention? - webull.com
Halozyme Therapeutics Prices $1.3 Billion Convertible Senior Notes with Additional $200 Million Overallotment Option - Kalkine Media
Dynatrace, Cava Group, Halozyme Therapeutics - TradingView
Halozyme Therapeutics, Etsy, Netflix - TradingView
Halozyme Therapeutics stock hits all-time high at 111.56 USD By Investing.com - Investing.com Nigeria
Halozyme Therapeutics stock hits all-time high at 111.56 USD - Investing.com
Halozyme prices $1.3B of 1.50% convertible notes due 2033, upsized with $200M option - TradingView
Halozyme Prices $1.3 Billion Convertible Senior Notes Offering - marketscreener.com
HALO Looks 10.2% Overvalued on GF Value™ - GuruFocus
Halozyme prices $1.3B convertible notes to fund repurchases and growth initiatives - Pluang
Halozyme prices $1.3 billion convertible notes offering - Investing.com
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 - PR Newswire
HALOZYME THERAPEUTICS (NASDAQ: HALO) Announces $1.05 Billion Convertible Senior Notes Offering with $150 Million Option - Kalkine Media
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Prices Upsized $1.3B 1.50% Convertible Notes Due 2033 - TradingView
Halozyme Therapeutics Plans $1.05 Billion Offering of Convertible Notes - marketscreener.com
Halozyme Therapeutics plans a $1.05B convertible notes sale - TradingView
Years of RSU awards set for sale by Halozyme (NASDAQ: HALO) director - stocktitan.net
Halozyme plans $1.05 billion convertible notes offering - Investing.com
Halozyme proposes $1.05B convertible notes due 2033, with $150M option - TradingView
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Plans $1.05B Convertible Notes Due 2033 - TradingView
Is Halozyme Therapeutics (HALO) Fully Priced Ahead Of Its September Conference Run? - Yahoo Finance
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):